Biological mechanisms and clinical efficacy of sulforaphane for mental disorders.
Wensi ZhengXiaolong LiTian Hong ZhangJijun WangPublished in: General psychiatry (2022)
Current clinical management of major mental disorders, such as autism spectrum disorder, depression and schizophrenia, is less than optimal. Recent scientific advances have indicated that deficits in oxidative and inflammation systems are extensively involved in the pathogenesis of these disorders. These findings have led to expanded considerations for treatment. Sulforaphane (SFN) is a dietary phytochemical extracted from cruciferous vegetables. It is an effective activator of the transcription factor nuclear erythroid-2 like factor-2, which can upregulate multiple antioxidants and protect neurons against various oxidative damages. On the other hand, it can also significantly reduce inflammatory response to pathological states and decrease the damage caused by the immune response via the nuclear factor-κB pathway and other pathways. In this review, we introduce the biological mechanisms of SFN and the pilot evidence from its clinical trials of major mental disorders, hoping to promote an increase in psychiatric clinical studies of SFN.
Keyphrases
- nuclear factor
- toll like receptor
- oxidative stress
- autism spectrum disorder
- immune response
- clinical trial
- transcription factor
- mental health
- depressive symptoms
- multidrug resistant
- attention deficit hyperactivity disorder
- randomized controlled trial
- inflammatory response
- study protocol
- sleep quality
- phase ii
- climate change
- risk assessment
- human health
- drinking water
- open label
- health risk assessment
- spinal cord injury
- working memory
- replacement therapy
- genome wide identification
- phase iii